J. P. M. Finberg - Concepedia

Author

J. P. M. Finberg

Rappaport Family Institute for Research in the Medical Sciences ORCID

Also Known As

Finberg, J. P. M., J FINBERG, J Finberg, J P Finberg, J P M Finberg, J. Finberg, J. P. Finberg, J. P. M. FINBERG, J. P. M. Finberg, J. P.M. Finberg

148

Publications

6.2K

Citations

H-Index

126

Concepts

All Affiliations

Rappaport Family Institute for Research in the Medical Sciences Technion – Israel Institute of Technology Rambam Health Care Campus National Institute of Neurological Disorders and Stroke National Institutes of Health

About

J. P. M. Finberg is an author at Rappaport Family Institute for Research in the Medical Sciences specializing in medicine, pharmacology, and neuroscience.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	48	2K
2	Health Sciences	10	10	387
3	Natural Sciences	5	5	338
4	Education	1	1	11
5	Engineering	1	1	40

J. P. M. Finberg

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B Moussa B. H. Youdim, Aviva Gross, J. P. M. Finberg British Journal of Pharmacology	2001	340
The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons Dorit Ben‐Shachar, G. Eshel, J. P. M. Finberg, Journal of Neurochemistry	1991	297
Copper pathology in vulnerable brain regions in Parkinson's disease Katherine M. Davies, Sylvain Bohic, Asunción Carmona, Neurobiology of Aging Neurological DisorderParkinson DiseaseCopper PathologyNeuroscienceNeurology	2013	237
Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug Chantal Moret, Marie Charvéron, J. P. M. Finberg, Neuropharmacology Medicinal ChemistryPharmacological StudyPsychiatryBiochemistryMedicine	1985	173
Effect of Long‐Term Treatment with Selective Monoamine Oxidase A and B Inhibitors on Dopamine Release from Rat Striatum In Vivo Itschak Lamensdorf, Moussa B. H. Youdim, J. P. M. Finberg Journal of Neurochemistry	1996	131
TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer’s disease Marta Weinstock, Corina Bejar, R.-H. Wang,	2000	116
Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor J. P. M. Finberg, Takao Takeshima, Jane M. Johnston, Neuroreport	1998	106
TYRAMINE ANTAGONISTIC PROPERTIES OF AGN 1135, AN IRREVERSIBLE INHIBITOR OF MONOAMINE OXIDASE TYPE B J. P. M. Finberg, M. Tenne, Moussa B. H. Youdim British Journal of Pharmacology	1981	103
Effect of Iron Chelators on Dopamine D<sub>2</sub> Receptors Dorit Ben‐Shachar, J. P. M. Finberg, Moussa B. H. Youdim Journal of Neurochemistry	1985	101
Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey J. P. M. Finberg, J. Wang, Krys S. Bankiewicz, Journal of neural transmission. Supplementum Selective InhibitionMonoamine Oxidase BStriatal Dopamine ProductionMedicinePsychopharmacology	1998	100

Page 1